NVIDIA Forges Partnerships to Revolutionize Healthcare with AI

NVIDIA Partners With Industry Leaders to Advance Genomics, Drug Discovery and Healthcare

J.P. Morgan Healthcare Conference -- NVIDIA today announced new partnerships to transform the $10 trillion healthcare and life sciences industry by accelerating drug discovery, enhancing genomic research and pioneering advanced healthcare services with agentic and generative AI. The convergence of AI, accelerated computing and biological data is turning healthcare into the largest technology industry. Healthcare leaders IQVIA, Illumina and Mayo Clinic, as well as Arc Institute, are using the latest NVIDIA technologies to develop solutions that will help advance human health. These solutions include AI agents that can speed clinical trials by reducing administrative burden, AI models that learn from biology instruments to advance drug discovery and digital pathology, and physical AI robots for surgery, patient monitoring and operations. AI agents, AI instruments and AI robots will help address the $3 trillion of operations dedicated to supporting industry growth and create an AI factory opportunity in the hundreds of billions of dollars. "AI offers an exceptional opportunity to advance healthcare and life sciences with tools that help providers detect diseases earlier and discover new treatments faster," said Kimberly Powell, vice president of healthcare at NVIDIA. "The combination of NVIDIA's AI and accelerated computing capabilities with the expertise of industry leaders is poised to usher in a new era of medical and biological innovation and improve patient outcomes worldwide." AI Foundry Services Boost Drug and Medical Device Development IQVIA -- a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries -- is using the NVIDIA AI Foundry service to build custom foundation models on its more than 64 petabytes of information, coupled with its deep domain expertise. The company is also developing agentic AI solutions, outfitted with NVIDIA AI Enterprise software including NVIDIA NIM™ microservices and NVIDIA Blueprints, that can speed research, clinical development and access to new treatments. IQVIA has been leading in the responsible use of AI, ensuring that its AI-powered capabilities are grounded in privacy, regulatory compliance and patient safety. "This represents a significant leap forward in how we apply AI to healthcare and life sciences," said Bhavik Patel, president of commercial solutions at IQVIA. "We are excited to combine our industry-leading capabilities and a decade of experience in artificial intelligence with NVIDIA's advanced AI technologies to build new solutions powered by AI agents that are trained on world-class healthcare information and optimized for life sciences workflows. This collaboration will advance our mission to help our clients accelerate innovation and treatments to market." Illumina and NVIDIA Supercharge Next Era of Genomic Breakthroughs Illumina, a global leader in DNA sequencing and informatics technologies, is working with NVIDIA to unlock the next generation of genomics for drug discovery and human health. This partnership will enable Illumina to use NVIDIA accelerated computing and AI toolsets for its multiomics analysis software and workflows. This will help make analysis of -- and insights from -- the human genome more accessible to researchers, pharmaceutical companies and other life sciences customers. Illumina will offer DRAGEN analysis software on NVIDIA accelerated computing within the Illumina Connected Analytics platform. The integration aims to expand DRAGEN accessibility globally to wherever NVIDIA's computing platform exists. Over the last five years, single-cell and spatial genomics have revolutionized drug discovery by providing unprecedented insights into cell understanding. To further expand the genomics market and help enable breakthroughs in target identification, clinical development and biomarker discovery, NVIDIA and Illumina plan to collaborate to progress multiomics data analysis on the Illumina Connected Analytics platform, in addition to developing new biology foundation models. The R&D community can more quickly and easily tap into rich genomic data by integrating NVIDIA RAPIDS™ accelerated data science software, included in the NVIDIA AI Enterprise software platform, with the NVIDIA BioNeMo™ platform's generative AI models and fine-tuning capabilities for proprietary datasets, and MONAI for spatial cell imaging workflows. Illumina and NVIDIA will work to make these tools accessible on the Illumina Connected Analytics platform. "Our ability to combine the power of AI with multiomics data is revolutionizing how we can understand disease," said Steve Barnard, chief technology officer at Illumina. "By combining Illumina's expertise in genomics data and analysis with NVIDIA's powerful AI platforms, we aim to enable pharma and biotech companies to unlock their own multiomics data to uncover transformative insights and improve success rates in developing lifesaving therapies." Mayo Clinic's AI-Powered Digital Pathology Pathology, an essential modality clinicians use to diagnose and determine treatments for many types of cancer and other serious and complex health conditions, is a historically slow and manual process. Mayo Clinic Digital Pathology platform, built from autonomous robotic labs and advanced imaging technology, offers a rich and unique dataset of 20 million whole-slide images with 10 million associated patient records to enable the creation of foundation models. Mayo Clinic and NVIDIA will massively accelerate the development of next-generation pathology foundation models. Mayo Clinic is planning to deploy newly available NVIDIA DGX™ Blackwell systems -- which are based on the NVIDIA Blackwell architecture and offer 1.4TB of GPU memory per system, ideal for handling digital pathology whole-slide datasets -- and NVIDIA's healthcare imaging platform MONAI. Mayo Clinic and NVIDIA are pioneering this work to serve as a cornerstone for future AI applications in drug discovery, and personalized diagnostics and treatments. The companies will continue to expand this collaboration with Mayo's clinical and AI expertise and NVIDIA Cosmos Nemotron vision language models and NIM microservices to provide more personalized healthcare experiences, along with predictive and efficient treatment strategies. Scaling Open Science Biology AI Models With Arc Institute Arc Institute, a Palo Alto, California-based research organization operating at the intersection of biology and machine learning, is collaborating with NVIDIA to develop and share powerful AI models and tools that advance biomedical discovery. Arc's biology and machine learning researchers are working with NVIDIA's engineers to scale the potential of foundation models for biology that can generalize across different modalities, like DNA, RNA and proteins, and advance applications for drug discovery, synthetic biology across multiple scales of complexity, disease and evolution research, and more. As part of the collaboration, NVIDIA has provided Arc Institute with expertise in large-scale model development; the NVIDIA BioNeMo platform running on NVIDIA DGX Cloud for easy-to-use, optimized training; and NVIDIA NIM microservices and Blueprints.

Nvidia partnerships aim to accelerate use of AI agents in healthcare research - SiliconANGLE

Nvidia partnerships aim to accelerate use of AI agents in healthcare research Nvidia Corp. today will use the J.P. Morgan Health Care Conference in San Francisco to announce multiple partnerships with healthcare technology firms aimed at apply artificial intelligence to speed up workflows in tasks ranging from drug discovery to genetic engineering. The partnerships are based on Nvidia's concept of "AI factories," which are data centers that transform raw data into actionable AI models, or "tokens," which serve as intelligent tools for various applications. The alliances are also aimed at developing more capable agents, which are digital robots that act autonomously with decision-making capabilities, often guided by goals or objectives. Agentic systems can plan, reason and execute tasks across multiple steps, adapt to changing environments and contexts, and go beyond answering questions to initiating actions. Nvidia said AI agents can now automate clinical documentation, assist patients in finding care, and even coordinate hospital operations during emergencies, such as natural disasters. "Nvidia has over 1,000 digital healthcare startups in our inception program alone who are developing thousands of AI agents," said Kimberly Powell. Nvidia's vice president of healthcare. She cited the example of clinical conversational generative AI platform Abridge Inc., which uses agents to automate clinical documentation, saving doctors up to three hours of clerical work per day. Nvidia is joining forces with Iqvia Holdings Inc., a provider of advanced analytics, technology and clinical research services for the life sciences industry, to streamline drug and medical device development. Iqvia's 64-petabyte proprietary anonymized data set will be used to train custom models using Nvidia's recently announced Llama Nemotron large language models "to drive more efficient clinical trial execution and workflow transformation with AI agents," Powell said. An alliance with the Mayo Clinic aims to co-develop a new generation of pathology models. Mayo will train Nvidia's DGX Blackwell systems and AI tools with over 20 million digital pathology images to create "digital twins," computerized replicas of physical entities, for personalized healthcare. A partnership with biotechnology firm Illumina Inc. aims to unlock insights from genomics data by combining Illumina's sequencing technology with Nvidia's AI tools. Nvidia said the collaboration will democratize genomics research and expand its applications in drug discovery. "We're going to unlock new markets for genomics by making not just the data, but the insights more accessible and driving significant advancements in disease research and drug discovery," Powell said. Nvidia is also teaming up with the nonprofit medical research organization Arc Institute to create open-source biological foundation models using Nvidia's BioNeMo natural language processing framework (pictured) for biology and clinical research. The goal is to advance the understanding of DNA, RNA and protein structures to advance biomedical research, Powell said. "Our partnership is going to focus on developing true foundation models for biology using BioNeMo and DGX cloud, with the resulting work contributed back to the open source in BioNeMo," she said. DGX Cloud is a cloud-based AI supercomputing service. The conference will also see the debut of a new release of BioNeMo called GenMol, a goal-directed molecular generation NeMo Inference Microservice for virtual screening. Nvidia is also releasing Blueprints for Protein Design, which are reference workflows for developing protein-based therapeutics. "Tens of thousands of life sciences companies, research institutes and platform companies can now integrate BioNeMo alongside traditional lab work, creating an AI drug discovery factory that the industry calls 'dry labs,'" Powell said. "We are seeing the transformation from a wet lab discovery process towards an AI factory, dry lab and moving drug discovery."

NVIDIA and IQVIA Build Domain-Expert Agentic AI for Healthcare and Life Sciences

IQVIA, the world's leading provider of clinical research services, commercial insights and healthcare intelligence, is working with NVIDIA to build custom foundation models and agentic AI workflows that can accelerate research, clinical development and access to new treatments. AI applications trained on the organization's vast healthcare-specific information and guided by its deep domain expertise will help the industry boost the efficiency of clinical trials and optimize planning for the launch of therapies and medical devices -- ultimately improving patient outcomes. Operating in over 100 countries, IQVIA has built the largest global healthcare network and is uniquely connected to the ecosystem with the most comprehensive and granular set of information, analytics and technologies in the industry. Announced today at the J.P. Morgan Conference in San Francisco, IQVIA's collection of models, AI agents and reference workflows will be developed with the NVIDIA AI Foundry platform for building custom models, allowing IQVIA's thousands of pharmaceutical, biotech and medical device customers to benefit from NVIDIA's agentic AI capabilities and IQVIA's technologies, life sciences information and expertise. The healthcare and life sciences industry generates more information than any other industry in the world, making up 30% of the world's data volume. IQVIA plans to use its unparalleled information assets, analytics and domain expertise -- known as IQVIA Connected Intelligence -- with the NVIDIA AI Foundry service to build language and multimodal foundational models that will power a collection of customized IQVIA AI agents. These agents are anticipated to be available in predefined workflows, or blueprints, that would accomplish a specific task. This partnership aims to accelerate the innovation cycle of IQVIA Healthcare-grade AI. IQVIA has been leading in the responsible use of AI, ensuring that its AI-powered capabilities are grounded in privacy, regulatory compliance and patient safety. IQVIA Healthcare-grade AI represents the company's commitment to these principles. One key opportunity area is in clinical development, when clinical trials are conducted for new drugs. The overall process takes about 11 years, on average, and each trial has a multitude of workflows that could be supported by AI agents. For example, just starting a clinical trial involves site selection, participant recruitment, regulatory submissions and tight communication between study sites and their sponsors. To streamline the development of these AI agents, IQVIA is using tools within NVIDIA AI Foundry and the NVIDIA AI Enterprise software platform, including NVIDIA NIM microservices, especially the Llama Nemotron and Cosmos Nemotron model families; NVIDIA AI Blueprint reference workflows; the NVIDIA NeMo platform for developing custom generative AI; and dedicated capacity on NVIDIA DGX Cloud. The NVIDIA AI Blueprint for multimodal PDF data extraction can help IQVIA unlock the immense amount of healthcare text, graphs, charts and tables stored in PDF files, bringing previously inaccessible information to train AI models and agents for domain-specific and even customer-specific applications. NVIDIA RAPIDS data science libraries then accelerate the construction of knowledge graphs. Additional AI agents could automate complex, time-consuming tasks, like document generation and patient recruitment, allowing healthcare professionals to focus on strategic decision-making and human interaction.

Nvidia Forges Partnerships to Tackle $10 Trillion Health Sector | PYMNTS.com

Nvidia has launched a series of partnerships designed to boost the healthcare sector via AI. The collaborations include work with a number of major figures in the $10 trillion healthcare field, the chipmaker announced Monday (Jan. 13) at the J.P. Morgan Healthcare Conference in San Francisco. "The convergence of AI, accelerated computing and biological data is turning healthcare into the largest technology industry," Nvidia said in a news release. "Healthcare leaders IQVIA, Illumina and Mayo Clinic, as well as Arc Institute, are using the latest Nvidia technologies to develop solutions that will help advance human health." These solutions include artificial intelligence (AI) agents that can speed clinical trials by reducing administrative burden, AI models that learn from biology instruments to advance drug discovery and digital pathology and physical AI robots for surgery, patient monitoring and operations. "AI agents, AI instruments and AI robots will help address the $3 trillion of operations dedicated to supporting industry growth and create an AI factory opportunity in the hundreds of billions of dollars," the company added. In the case of the Mayo Clinic, the medical center will use Nvidia's tech to accelerate the development of new pathology foundation models. DNA sequencing and informatics technology provider Illumina, meanwhile, will employ Nvidia accelerated computing and AI toolsets for its multiomics analysis software and workflows. "This will help make analysis of -- and insights from -- the human genome more accessible to researchers, pharmaceutical companies and other life sciences customers," the release said. The announcement comes one week after Nvidia CEO Jensen Huang introduced several new developments from the company, including next-generation chips, new large language models and a mini AI supercomputer, while also announcing a partnership with Toyota. "It's been an extraordinary journey, extraordinary year," Huang said to a packed crowd during a keynote address at the CES trade show in Las Vegas. Last year saw Nvidia become one of the world's most valuable companies in terms of market value. It currently occupies the No. 2 spot, at $3.2 trillion -- right below $3.4 trillion Apple. It was a year, PYMNTS wrote earlier this month, that saw AI capabilities move from simple automation to tackle complex tasks in fields like healthcare but also finance and manufacturing. "By year's end, tech's landscape had fundamentally shifted. AI wasn't just another feature or stock catalyst -- it had become the lens through which companies viewed their futures," that report said. "The question shifted from whether AI would transform business to how companies would harness its potential."